Cookie Preferences
By clicking “Accept All”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage and assist in our marketing efforts as outlined in our cookie policy.
Strictly Necessary (Always Active)
Cookies required to enable basic website functionality.
Cookies helping us understand how this website performs, how visitors interact with the site, and whether there may be technical issues.
Cookies used to deliver advertising that is more relevant to you and your interests.
Cookies allowing the website to remember choices you make (such as your user name, language, or the region you are in).

Ventures

Invest in breakthrough healthtech solutions that transform patients' lives.

00:00
/
00:00
00:00
/
00:00
Invest in transformative health innovations
Invest in transformative health innovations

We vet over 1500 innovations yearly and identify, build, and invest in 20 to 25 ventures that address crucial, unmet needs in the healthcare sector. Our ventures lead in areas such as personalized medicine, AI diagnostics, and medical devices, all of which show substantial potential for growth, return, and impact.

00:00
/
00:00
00:00
/
00:00
Invest alongside NLC
Invest alongside NLC

As an investor in an NLC venture, you always invest alongside NLC. Our team of 80+ experts offers comprehensive support to our ventures, including regulatory guidance, product development assistance, and clinical trial setup. This extensive, tailored support system de-risks your investment and enhances the likelihood of venture success. Single-company investments start at €25K.

00:00
/
00:00
00:00
/
00:00
Invest with impact
Invest with impact

By investing in one of our ventures, you help bring transformative health solutions to patients in need, directly impacting their lives. NLC is a certified B Corp and supports UN Sustainable Development Goals 3, 9, and 17, our funds are SDFR-9 compliant, which means we adhere to the strictest impact regulations. Investing in NLC ventures can be your pathway to high-impact capital deployment.

Receive the latest investment opportunities that match your interests, directly in your inbox. Stay informed and never miss out.

a highlight from our portfolio

Angiogenesis Analytics

Angiogenesis Analytics

Angiogenesis Analytics is transforming prostate cancer diagnosis by integrating artificial intelligence with advanced ultrasound technology. Our mission is to make the detection of prostate cancer quicker, more affordable, and significantly less invasive than traditional methods. By pioneering the innovative PCAVision technology, we are setting new standards in healthcare.
Visit website
Download documents
PEP Health

PEP Health

PEP Health is revolutionizing how healthcare providers understand and improve patient experiences by leveraging machine-learning technology to give healthcare organizations, regulators, and insurers the real-time, actionable insights they need to have a direct and dramatic impact on patient experiences.
Visit website
Download documents
Capnosway
Direct CO2 measurement at the patient's nose or mouth, simplifying setup and improving accuracy

Capnosway introduces a CO2 monitoring device designed to address the shortcomings of traditional anesthesia. Developed by Philips, this solution directly measures CO2 concentration at the patient's mouth or nose without the need for air sampling. By eliminating procedures, and potential errors associated, Capnosway ensures accurate and efficient monitoring for medical professionals.

Active
🇳🇱 Netherlands
Capnosway
Nilocas
A cardiac device for the detection of coronary artery disease

Nilocas offers a revolutionary solution for detecting coronary artery disease non-invasively and without radiation. Patients wear a lightweight chest patch that captures the sounds of turbulent blood flow through arteries using microphones and accelerometers. Advanced machine learning and AI rapidly analyze the data, providing a clear diagnosis in just 10 minutes. This innovation eliminates the need for costly and invasive procedures, making cardiac diagnosis more accessible in both clinical and non-clinical settings.

Active
🇬🇧 United Kingdom
Nilocas
Angiogenesis Analytics
Detecting, locating, and characterizing prostate cancer using ultrasound

Angiogenesis Analytics, offers an ultrasound-based solution for detecting, localizing, and characterizing prostate cancer. Each year, over 1.5 million men undergo invasive biopsies with risks of infection, false negatives, and overtreatment. Angiogenesis Analytics eliminates these issues by providing a non-invasive, accurate, and cost-effective alternative, improving patient comfort and outcomes. With an estimated market value of USD 450 million annually, Angiogenesis Analytics addresses a significant global need for better prostate cancer diagnostics.

Active
🇳🇱 Netherlands
Angiogenesis Analytics
ProVascTec
Transforming arterial disease treatment with cell therapy

ProVascTec offers a novel solution for chronic arterial disease, focusing on peripheral arterial disease (PAD) and chronic limb ischemia. Unlike traditional treatments like angioplasty or bypass surgery, ProVascTec aims to stimulate vascular tissue growth using mesenchymal stem cells, reducing complications and improving blood flow. This innovative approach has the potential to benefit millions of patients suffering from PAD worldwide.

Active
🇮🇪 Ireland
ProVascTec
Karla Therapeutics
Innovating mental health treatments through neuroimmunology

Karla Therapeutics is exploring an approach, treating mental disorders by leveraging our immune system. Neurodevelopmental disorders like ADHD and OCD are increasingly prevalent, yet treatment options often have side effects and limited effectiveness. By bridging between the immune system and mental health, Karla aims to revolutionize treatment methods. Their research focuses on a specific protein identified by top-tier immunologists, showing promising results in early experiments for OCD, anxiety, and ADHD.

Active
🇫🇷 France
Karla Therapeutics
Charm
Empowering low-resource healthcare professionals around the world

ChARM, or the Children’s Automated Respiration Monitor, addresses the challenge of pneumonia misdiagnosis in low-resource settings. This battery-powered device provides accurate breathing rate monitoring for children under five, empowering healthcare workers to make correct diagnoses swiftly. By streamlining the diagnostic process, ChARM facilitates timely treatment, potentially saving thousands of young lives annually.

Active
🇳🇱 Netherlands
Charm
MindAffect
Building the next generation of hearing & vision diagnostics

MindAffect aims to diagnose visual and hearing impairments in over 2 billion people, including children, seniors, and the disabled, leading to untreated impairments and significant societal costs. Their innovative brain computer interface and AI technology offer a solution by analyzing brain responses to auditory or visual stimuli, reducing testing time and improving accuracy.

Active
🇳🇱 Netherlands
MindAffect
Ecomedic
Enabling a 'net zero' emission in health sector

Ecomedic is dedicated to helping hospitals reduce their carbon footprint, addressing the healthcare sector's contribution to global emissions. Ecomedic's database and software tools enable environmental impact analyses, identify sources of emissions and measures the effect of alternative solutions. By providing insights and solutions, the institutions are supported in achieving their carbon neutrality goals and reducing operational costs.

Active
🇬🇧 United Kingdom
Ecomedic

Our impact

15
Countries active in
2.4M
Patients impacted
20-25
Ventures built annually
70+
Active ventures in our portfolio
80+
Healthcare experts
€160M+
Raised by NLC ventures

Explore our 2024 Impact report

Woman with hands in the air in nature
Maurits Schouten
00:00
/
00:00
I consider the medical sector to be very attractive. However, without the right expertise, network, and diversification, the risks can be significant. NLC removes these barriers and creates an attractive opportunity for me to participate as an investor in this sector.
Maurits Schouten

Maurits Schouten

Impact investor and Board Member of PYM

Peter Veldman
00:00
/
00:00
What I really like about NLC and what triggered my investment in the company is the strong culture and the quality of the team. NLC is able to de-risk the innovation cycle by building ventures at scale, thereby playing a leading role in shaping the future of healthcare.
Peter Veldman

Peter Veldman

Advisor and previous Deputy Head of Fund Operations at EQT Group

Invest in a portfolio of companies

A formal clothed man on a bridge in the city

Create a healthier future with us

Lars Olthof
Head of Venture Finance, Venture Investment Director